
Dr. Weidinger discusses the intricate neuroinflammatory mechanisms of chronic pruritic skin disease such as AD and PN.
Experience a pediatric patient's journey from infancy to adolescence with guideline-based learnings on EoE diagnosis, treatment, and long-term care.
Join Prof. Sietze Reitsma for an insightful presentation that will delve into identifying and leveraging key characteristics to optimize patient management and treatment outcomes.
Meet Fernando. Journey through his clinical profile, applying guideline-based checklists to reach a consensus regarding his diagnosis.

Dr. Paller discusses factors influencing AD chronicity and comorbidities, focusing on disease severity, early onset, heredity, multiple allergies, and urban living as important in evaluating AD’s lasting effects on children.
Professor Matthias Augustin highlights the high prevalence of both atopic and non-atopic comorbidities in patients with PN, including increased risks of cardiovascular events and all-cause mortality.

Dr Kwatra poses the question: How do we assess disease modification in PN, and can treating early stop tissue damage and worsening of systemic diseases associated with PN?
Prof Jean-David Bouaziz describes the multifaceted burden of atopic dermatitis, beyond what can be seen on the skin, at EADV 2025.

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.